AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation (CDSO) for the import, sale, and distribution of Durvalumab.
Shares of AstraZeneca Pharma India surged by 13% during Tuesday’s trading session, reaching an intraday high of ₹7,598. The stock has recorded a 34% gain in 2024 so far.
Durvalumab, combined with chemotherapy, is approved as a neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC) with tumors over 4 cm or node-positive, excluding EGFR mutations or ALK rearrangements.
Post-surgery, the treatment will continue with Imfinzi alone. The company plans to launch Durvalumab in 120 mg/2.4 mL and 500 mg/10 mL solutions in India, pending statutory approvals. This regulatory approval is expected to support the company’s expansion in the Indian market.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
